Domain Associates is a venture capital firm with an exclusive focus on life sciences, investing in biopharmaceutical, medical device, diagnostic, and healthcare IT companies. Founded in 1985, the firm has managed over $2.8 billion in assets and backed more than 194 portfolio companies resulting in 90 IPOs and 110 M&A events.
Average disclosed round size is $32.7M (across 150 rounds with reported amounts).
Portfolio
97
Fund Size
$163.6M
Top Stage
Series B
Last 12 Mo
0
Team
LK
Lisa Kraeutler
Managing Director of Finance and Administration
DP
Dennis Podlesak
Venture Partner
EW
Eckard Weber
Venture Partner
JB
James Blair
Partner
KS
Kathleen Schoemaker
Partner and CFO (In Memorium 2016)
DL
Debra Liebert
Managing Director
JB
Jim Blair
Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
163 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Sera Prognostics | Series E | $100M | Jan 2026 |
| RRevision | Series D | — | Jan 2026 |
| AAntios Therapeutics, Inc. | Series A | $75M | Nov 2021 |
| AAxial Therapeutics | Series C | $37.3M | Oct 2021 |
| AAntios Therapeutics, Inc. | Series B | $96M | Apr 2021 |
| AAntios Therapeutics, Inc. | Series B | $96M | Jan 2021 |
 Exalys Therapeutics Inc. | Series A | $15M | Jul 2020 |
 Aspen Neuroscience | Series A | $70M | Apr 2020 |
 Omniome | Series C | $60M | Jan 2020 |
 Seraphina Therapeutics | Series A | $5.5M | Jan 2020 |
| Aspen Neuroscience | Seed | $6.5M | Dec 2019 |
| Sera Prognostics | Series D | $36M | Nov 2019 |
| Sera Prognostics | Series D | $36M | Jan 2019 |
| Omniome | Series B | $60M | Jul 2018 |
| Omniome | Series B | $60M | Jan 2018 |
 Milestone Pharmaceuticals | Series C | $55M | Aug 2017 |
 Adynxx | Series B | $16M | Jan 2017 |
| Sera Prognostics | Series C | $40M | Jan 2017 |
 ROX Medical | Series E | $40M | Sep 2016 |
 Axial Biotherapeutics | Series A | $19.1M | Jan 2016 |
| RRevision | Unknown | $32M | Jan 2016 |
 Syndax Pharmaceuticals | Series C | $80M | Aug 2015 |
| Milestone Pharmaceuticals | Series B | $17M | Jun 2015 |
 Colucid Pharmaceuticals | Series C | $37.1M | Jan 2015 |
 Syndax | Series C | $80M | Jan 2015 |
Page 1 of 7
Top Co-Investors
InterWest Partners19 shared
Canaan Partners17 shared
Sofinnova Partners12 shared
Frazier Healthcare Partners11 shared
OrbiMed10 shared
Versant Ventures10 shared
Pappas Capital10 shared
ARCH Venture Partners9 shared
Hercules Capital, Inc.8 shared
Forward Partners7 shared
Cross Creek7 shared
Novo Holdings A/S7 shared
Scale Venture Partners7 shared
New Enterprise Associates7 shared
Health Catalyst Capital6 shared
MPM Capital6 shared
Abingworth LLP6 shared
Alta Partners5 shared
Osage University Partners5 shared
Delos Capital5 shared
Last updated: 7 October 2026